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First of all, the experimental design of 
any project should be conducted consider-
ing the ultimate target of every study: the 
human being. Unreal situations or vague 
advances that do not reflect reliable patterns 
of “improvement” could be re-designed to 
be smart and feasible studies. For example, 
the common phrases in academic research 
such as “positive effects” or “preclinical and 
clinical evidence” become “efficient, safe, and 
commercially viable” inside industry (1). 
Reproducibility of results from the laboratory 
bench is a challenge. For instance, in oncol-
ogy research, only 11% of targets identified 
in preclinical studies were verified as reliable 
for development in early stage industry stud-
ies, and up to two-thirds of projects based 
on published literature end up terminated 
due to lack of reproducibility (1, 2). This 
occurrence is also very common in neuro-
science research. Poor reproducibility was 
the first point addressed in the guidelines 
for preclinical research in epilepsy (3) and 
demonstrated by the “Facilities of Research 
Excellence-Spinal Cord Injury” project (4–6). 
At the same time, the cost of development 
for a new anti-seizure therapy is around 
one billion dollars for industry, and in the 
last decades few therapies were successfully 
applied in patients with uncontrolled sei-
zures (3). In view of these facts, it is hard 
for the pharmaceutical industry to apply 
the knowledge emerging from the major-
ity of academic studies. Although it is very 
exciting that a substance “X” improved the 
neurological tissue in the brain; can this 
substance modulate the main symptom of 
a specific neurological disease? Can this sub-
stance reliably induce a significant effect in 
different strains of cells, in vivo models, and 
humans? We agree that this “ideal” approach 
to research is hard to establish mainly in lab-
oratories with limited grants for  extensive 
In the last years, many  pharmaceutical 
 companies have closed their doors of 
research and development department, 
which in turn, resulted in the transference 
of commercial investments to universities. 
The commercial trend will become aca-
demic research more important than ever. 
Nowadays, the collaboration between the sci-
entific community and companies becomes 
a reality. In this sense, how many academic 
studies have been published in compliance 
with international guidelines required for 
regulatory agencies? Unfortunately, few 
of them. The reproducibility of academic 
studies is a challenge that affects directly the 
success of a new clinical trial conducted by 
pharmaceutical industries.
This scenario was recognized by academic 
scientists and a platform for independent vali-
dation was created for articles already pub-
lished1. Indeed, actions such as new editorial 
measures have just introduced in order to 
reduce the irreproducibility of scientific stud-
ies2. In this context, it is required the transpar-
ency of methods section, which will benefit 
the evaluation of the Reviewers and the repro-
duction of the study as well. For instance, it 
is mandatory the detailed description of rea-
gents, inclusion and exclusion criteria, blind-
ing, biological replicates, and accession codes 
for genetic material in animal studies.
However, there are other factors inherent 
in any academic researcher that are often 
ignored and undoubtedly corroborate to 
pitfalls in scientific results. We would like to 
expose here some suggestions for Academy 
to improve their work and increases the 
probability in translate their researches into 
commercial setting.
studies. In this context,  collaborations 
between different  departments, universi-
ties, and research fields could be an excellent 
alternative. Furthermore, is a unique oppor-
tunity to experience other point-of-views 
and researches fields, which could in turn, 
facilitate the development of new innovative 
and audacious ideas. The multidisciplinary 
staff is absolutely required for projects that 
result in robust data and significant advances, 
and not only an article that will be stored in a 
drawer. An interesting example of collabora-
tion comes from private side: in 2012, the 10 
biggest pharmaceutical companies joined and 
launched the TransCelerate Biopharma Inc, a 
non-profit organization with a common goal: 
to accelerate the medication development.
The second point that deserves discus-
sion is the beliefs and paradigms of academic 
scientists. It is hard for academic researchers 
to accept that extensive and difficult work 
performed in their laboratories may result 
in no significant effect or even findings that 
oppose the current literature, both of which 
are extremely difficult to publish. This posi-
tion is understandable if it takes into account 
the time spent on a project. In many cases, a 
single researcher is responsible for the entire 
experimental design. Opposite effects or 
insignificance are two of the greatest fears 
of any academic scientist, all of whom need 
to publish more than ever. However, if 
experiments with negative results meet all 
the necessary quality criteria (i.e., replica-
tion of experiments), unexpected or contra-
dictory data should be published and well 
accepted by the editors, reviewers, and gen-
eral scientific community (2). The break of 
paradigms regarding negative results should 
be priority in the academic research. For 
instance, phosphodiesterase type-5 inhibi-
tor (PDEI-5) is a first-line oral treatment for 
erectile dysfunction in men (7, 8). The clear 
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this link. This is the third and perhaps the 
major obstacle inside the walls of univer-
sity: to break the prejudice of academic 
researches into work together with industry. 
However, it is important for researches to 
known that the better institutions around 
the world received important investments 
from the giant pharmaceutical industries, 
which joined with other companies mainly 
in clinical trials. The development of “col-
lective” science is a trend inside industry 
(19) and Academy could gain with new 
business posture. Investments in infrastruc-
ture, staff, and supplies can be the major 
advantages for this collaboration. There 
are global programs from pharmaceutical 
industries available for all researches which 
would like to test their products.
As described above, the difficulties in 
translating academic findings to industry 
successes may be influenced by problems 
inherent in the current academic system. 
It is important for all of us to remember, 
regardless of ideology and goal of any sci-
ence professional, academic, or industry, 
that we all have the same objective: the 
progress of science.
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 beneficial effects were extensively described 
in the literature, and after 10 years of analysis 
of adverse effects, PDEI-5 is considered safe 
with minimum adverse effects in men (9, 
10). However, case reports and data from 
animal models indicated that, in particular 
cases, PDEI-5 should be prescribed with 
caution, as it may play a role in seizure sus-
ceptibility (11). This is an excellent example 
of why journals should accept papers with 
robust data commonly different from those 
published in the literature. In addition, the 
lack of negative results represents a direct 
problem for clinical translation of new com-
pounds, medications, and devices. Publish 
negative data can avoid that other colleagues 
and pharmaceutical industries waste money 
and time in the conduction of non-signifi-
cant experiments (12).
On the other hand, academic profes-
sionals are constantly pressured to publish, 
which in turn results in grants, prestige, 
and career advancement (13–15). In the 
majority of scientific journals, it is man-
datory to declare any conflict of interest. 
According to The American Academy of 
Neurology and its affiliated organizations 
(AAN), those who have any relationship 
with industry (medical devices, pharma-
ceutical, or another commercial product), 
and receive benefits from this relationship, 
could be influenced by financial conflicts 
of interest (16). This type of financial con-
flict is very common among physicians and 
is the subject of many reviews and inter-
national guidelines (17). However, the 
“publish or perish” culture of academia is 
not yet acknowledged to represent a simi-
lar conflict of interest. We recognize that 
desire for success is an inherent feeling in 
any scientist; however, the quality and reli-
ability of data must be the priority for any 
academic competition. Fortunately, the first 
step of adequate individual scientific per-
formance evaluation was made: according 
the recommendations of the San Francisco 
Declaration on Research Assessment the 
journal impact factor will not take into 
account in the curricula vitae (18).
A meeting composed by academic and 
business leaders discussed the fragile rela-
tionship between Academy and industry3. 
They recognized the urgency to strengthen 
3 http://www.icsu.org/publications/cfrs/scientific-rela-
tions-between-academia-and-industry-building-on-
a-new-era-of-interactions-for-the-benefit-of-society
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